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SUMMARY
Despite the importance of the co-receptor PD-1 in
T cell immunity, the upstream signaling pathway
that regulates PD-1 expression has not been defined.
Glycogen synthase kinase 3 (GSK-3, isoforms a and
b) is a serine-threonine kinase implicated in cellular
processes. Here, we identified GSK-3 as a key up-
stream kinase that regulated PD-1 expression in
CD8+ T cells. GSK-3 siRNA downregulation, or inhibi-
tion by small molecules, blocked PD-1 expression,
resulting in increased CD8+ cytotoxic T lymphocyte
(CTL) function. Mechanistically, GSK-3 inactivation
increased Tbx21 transcription, promoting enhanced
T-bet expression and subsequent suppression of
Pdcd1 (encodes PD-1) transcription in CD8+ CTLs.
Injection of GSK-3 inhibitors inmice increased in vivo
CD8+ OT-I CTL function and the clearance of murine
gamma-herpesvirus 68 and lymphocytic choriome-
ningitis clone 13 and reversed T cell exhaustion.
Our findings identify GSK-3 as a regulator of PD-1
expression and demonstrate the applicability of
GSK-3 inhibitors in the modulation of PD-1 in immu-
notherapy.
INTRODUCTION
Persistent viral infections are often associated with the functional
exhaustion of virus-specific CD8+ T cells (Virgin et al., 2009). Ex-
hausted T cells have diminished effector functions and a distinct
transcriptional profile relative to effector cells (Wherry, 2011). Re-
ceptor programmed death 1 (PD-1; also known as PDCD1)
expression is upregulated on the surface of exhausted CD8+
T cells in mice infected by the lymphocytic choriomeningitis virus
clone 13 strain (LCMV-Cl13) (Barber et al., 2006; Day et al., 2006;
Freeman et al., 2006; Sharpe et al., 2007). PD-1 is also upregu-
lated during infection by the human immunodeficiency virus-1
(HIV-1) (Day et al., 2006) and hepatitis C virus (Evans et al.,
2008) and in monkeys infected with the simian immunodefi-
ciency virus (SIV) (Velu et al., 2009) and correlates with increased
viral load (Barber et al., 2006; Blattman et al., 2009; Day et al.,
2006; Palmer et al., 2013). Blocking antibodies against PD-1
restores CD8+ T cell functionality and viral clearance (Freeman
et al., 2006; Ha et al., 2008; Sharpe et al., 2007; Wherry, 2011).
Checkpoint inhibitor blockade has also proven effective in the
treatment of cancers such as melanoma (Hodi et al., 2003,
2010) and in combined therapy with anti-CTLA-4 (Topalian
et al., 2015; Wolchok et al., 2013).
Two ligands, PD-L1 and PD-L2, have been identified for PD-1
(Freeman et al., 2000; Latchman et al., 2001; Sharpe and
Freeman, 2002; Ishida et al., 2002), and PD-1 has an immunore-
ceptor tyrosine-based switch motif (ITSM) that binds Src
homology region 2 domain-containing phosphatases SHP-1
and SHP-2 (Chemnitz et al., 2004; Okazaki et al., 2001). The pre-
ponderance of studies are compatible with a negative function
for the co-receptor (Dong et al., 1999; Freeman et al., 2000;
Latchman et al., 2001; Nishimura et al., 2001; Tseng et al.,
2001). Co-ligation can de-phosphorylate signaling proteins
(Chemnitz et al., 2004; Parry et al., 2005; Yokosuka et al.,
2012) and form micro-clusters (Yokosuka et al., 2012). PD-1
can also upregulate inhibitory basic leucine zipper transcription
factor, ATF-like BATF (Quigley et al., 2010), and induce motility
paralysis (Zinselmeyer et al., 2013).
Despite this, the signal transduction pathway that regulates
PD-1 transcription and expression in T cells has not been fully
defined. Tyrosine kinases p56lck and ZAP-70 activate T cells
(Rudd, 1999; Weiss and Littman, 1994). Src kinase p56lck binds
CD4 and CD8 (Barber et al., 1989; Rudd et al., 1988; Veillette
et al., 1989) and phosphorylates the TCR complex for ZAP-70
recruitment and phosphorylation of adaptors (Barber et al.,
1989; Burgess et al., 1991; Chan et al., 1992; Rudd, 1999;
Samelson, 2002; Weiss and Littman, 1994). By contrast, the
serine/threonine kinase, glycogen synthase kinase 3 (GSK-3),
first characterized in phosphorylating glycogen synthase, is
constitutively active in resting T cells (Frame and Cohen, 2001;
Woodgett, 1990). Two isoforms of GSK-3 (a and b) have similar
kinase domains but divergent N and C termini. They influence
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multiple signaling pathways although the two isoforms have
distinct roles in cell survival (Frame and Cohen, 2001). In CD4+
T cells, GSK-3 facilitates the exit of nuclear factor of activated
T cells (NFAT) from the nucleus (Beals et al., 1997; Neal and
Clipstone, 2001). TCR and CD28 phosphorylate and inactivate
GSK-3 (Ohteki et al., 2000; Wood et al., 2006), and constitutively
active GSK-3b (GSK-3bA9) inhibits the proliferation of T cells
(Ohteki et al., 2000). GSK-3 in T cells operates independently of
guanine nucleotide exchange factor VAV-1 (Wood et al., 2006).
Although certain transcription factors have been implicated
in Pdcd1 transcription, the identity of the upstream signaling
event(s) that control PD-1 expression has been unclear. Here,
we have identified GSK-3a and GSK-3b (hereafter referred to
as GSK-3 collectively) as a key kinase that upregulated Tbx21
transcription for the downregulation of PD-1 and enhanced
CD8+ cytolytic T cell function. We also demonstrated the use
of small molecule inhibitors of GSK-3 to downregulate PD-1 for
enhanced in vivo immunity involving the clearance of acute
and chronic viral infections.
RESULTS
GSK-3 Downregulation or Inhibition Augments Cytolytic
Killing of OT-I Transgenic T Cells
Although GSK-3 inhibits T cell expansion (Appleman et al., 2000;
Ohteki et al., 2000; Wood et al., 2006), its role in the function
of cytolytic T lymphocytes (CTLs) is not clear. To examine
this, we initially examined CTL responses of T cells from OT-I
transgenic mice that carry a MHC class I-restricted T cell recep-
tor (TCR) specific for the SIINFEKL peptide of OVAlbumin
(OVA257-264) as presented by H-2k
b. T cells express the a and
b isoforms of GSK-3 (Cohen and Frame, 2001). Small interfering
RNAs (siRNAs) to the GSK-3a and b isoforms were used to
knock down (KD) their expression in naive T cells by transfection
prior to use in functional assays. siRNA treatment reduced GSK-
3a and b protein substantially as seen by Western blotting (Fig-
ure 1A, iii), and by using fluorescent FITC-conjugated siRNAs,
we found that more than 80% of cells had taken up the siRNAs
(Figure 1A, iii). Further, siRNAs to GSK-3 increased OT-I-medi-
ated cytolysis of mouse lymphoma cell line EL4-OVA targets
significantly when compared to the control scrambled siRNA
control (Figure 1A, i). There was a linear increase in killing of con-
trol samples expressing scrambled siRNAs across effector:tar-
get (E:T) ratios of 2:1 to 50:1 when assayed at day 5. This was
confirmed by Scatchard plot analysis (r2 = 0.9603) (Figure 1A,
iv). By contrast, the KD of GSK-3 increased the efficiency of
CTL killing. The increase in killing efficiency seen was 3- to
5-fold for E:T ratios of 2:1 and 5:1. An E:T ratio of 2:1 showed
the same efficiency of killing as seen at a ratio of 25:1 for control
scrambled cells (i.e., p value = 0.333). A similar potentiating ef-
fect was also evident when assayed at days 4 and 7 (data not
shown). These data showed that the KD of GSK-3 markedly
increased the killing capacity of CD8+ OT-I cytolytic T cells.
ATP competitive and non-competitive inhibitors of GSK-3
kinase activity exist (Cohen and Goedert, 2004). SB415286
competitively inhibits both isoforms with a preference of the b
isoform (Coghlan et al., 2000). Similar to the GSK-3 KD, inhibition
of GSK-3 catalytic activity with SB415286 increased the killing
efficiency of CTLs (Figure 1B, i). The linear increase (Figure 1B,
iii) in the killing over E:T ratios was confirmed by Scatchard
plot analysis (r2 = 0.9643). Incubation of OT-I T cells with
SB415286 increased maximal killing by as much as 5-fold
and shifted the killing curve by 10-fold (i.e., p value = 0.111).
SB415286 also increased proliferation in response to OVA
peptide to the same extent as when cells were cultured with
anti-PD-1, as monitored by carboxyfluorescein succinimidyl
ester (CFSE) labeling (Figure S1A). Cell counting with trypan
blue exclusion showed that SB415286 increased slightly the
cell number in response to anti-CD3 (Figure S1B) and had no ef-
fect on cell viability (Figure S1C). These results showed that
GSK-3 inactivation increases the killing efficiency of CD8-posi-
tive CTLs.
GSK-3 Downregulation or Inhibition Selectively Inhibits
PD-1 Expression
We next assessed the effect of GSK-3 inhibition on receptor
expression (Figure 1A, ii). GSK-3 siRNA reduced the frequency
of cell surface expression PD-1 from 30% of cells to 7% of cells
and also decreased the mean fluorescent intensity (MFI) of PD-1
expression without affecting CD28 or CTLA-4 expression.
SB415286 reduced the frequency of cell expressing surface
PD-1 expression on 54% to 7% of cells and decreased the MFI
without affecting CTLA-4 or CD28 (Figure 1B, ii). Resting cells
failed to express PD-1 or CTLA-4 (Figure S1D). The expression
of CD44, CD62L, Tim3, CD3, BTLA, NKG2D, CD122, interleukin
2 receptor-alpha (IL-2Ra), CD25, CD69, Fas-ligand (FasL), CD8,
and IL-2 was also unaffected by SB415286 (Figure 1C). Similarly,
the expression of intracellular IL-2 and anti-apoptotic protein
Bcl-2 was unaffected. However, consistent with enhanced CTL
function, the frequency of cells expressing interferon-g (IFN-g),
lysosomal-associated membrane protein 1 (Lamp1; CD107a),
and cytotoxic T-lymphocyte-associated serine esterase 1 (Gran-
zyme B; GZMB) was increased on OT-I CD8+ T cells.
siRNA selective for the GSK-3a isoform also reduced PD-1
expression while increasing OT-I killing (Figure 1D, iii and i). It
reduced GSK-3a expression as confirmed by anti-GSK-3a blot-
ting (Figure 1D, ii) and by flow cytometry (Figure 1D, iii) without
affecting GSK-3b cell surface expression. siRNA GSK-3b was
also tested but failed to show specificity and was not pursued
(data not shown). These data showed that GSK-3a siRNA KD
alone could downregulate PD-1 and increase the killing effi-
ciency of CTLs.
Other structurally distinct inhibitors of GSK-3 decreased
PD-1 expression and potentiated OT-I killing of targets (Fig-
ure 1E). These included ATP-competitive inhibitors SB216763,
CHIR99021, and L803-mts, where SB216763 has a preference
for the GSK-3a isoform and CHIR99021 and L803-mts preferen-
tially inhibited GSK-3b (Kaidanovich-Beilin and Eldar-Finkelman,
2006).
We next determinedwhether the reduction of PD-1 expression
by GSK-3 inhibition was itself responsible for the enhanced CTL
function by blocking with anti-PD-1 or PD L1-Fc (constant frag-
ment) in the absence and presence of GSK-3 inactivation (Fig-
ure 2). PD-1 blockade increased the CTL killing efficiency to
the same extent as GSK-3 siRNA as seen over multiple E:T ratios
(Figure 2A). However, the addition of PD-1 or PD L1-Fc to GSK-3
siRNA-expressing cells did not increase killing beyond that seen
with GSK-3 inactivation alone or vice versa. Identical results
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were obtained using anti-PD-1 or PDL1-Fc with SB415286
where blockade did not increase killing beyond that seen with
the inhibitor, and vice versa (Figure 2B). Similar results were
obtained using GSK-3 inhibitor SB216763 in combination with
anti-PD-1 (Figure S2).
siRNA KD of PD-1 expression in CD8+ T cells also increased
cytolytic function (Figure 2D). PD-1 siRNA and SB415286 each
reduced pdcd1 transcription by >85% reduction (Figure 2C)
and enhancedCTL killing to the same degree. Further, combined
siRNA and SB415286 increased CTL function no further than
seen with either treatment alone. These observations confirmed
that the modulatory effect of GSK-3 inactivation on OT-I CTL
function was primarily due to PD-1 down-modulation.
GSK-3 Downregulation or Inhibition Blocks PD-1
Transcription
We next confirmed that GSK-3 inactivation acted on Pdcd1 tran-
scription (encodes PD-1) in different contexts (Figure 3). Anti-
CD3 ligation induces PD-1 expression on T cells (Agata et al.,
1996). Two-step real-time PCRwas used to separate the reverse
transcription reaction from the real-time PCR assay (Wacker and
Godard, 2005). The presence of SB415286 was remarkably
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Figure 1. GSK-3 Inactivation via siRNA KD or Small Molecule Inhibitors Specifically Downregulated PD-1 Expression with Enhanced CTL
Function
(A) i: siRNA against GSK3 increases the cytolytic killing of OT-I CD8+ T cells. Scrambled siRNA (gray bars), siRNA against GSK3 (blue bars) (n = 5). ii: Flow
cytometry profiles of receptor expression (gray line, isotype control; green line, scrambled siRNA; red line, GSK3 siRNA). iii: Anti-GSK3 blotting of cell lysates;
FITC-tagged siRNA uptake. iv: Scatchard plot analysis.
(B) i: OT-I T cells were incubated without (gray bars) or with SB415286 (blue bars) (n = 5). ii: Flow cytometry profiles (as above except red line: SB415286). iii:
Scatchard plot analysis.
(C) Flow cytometry profiles. Gray line, isotype control; green line, untreated cells; red line, cells incubated with SB415286.
(D) i: Cytolytic assay using GSK-3a siRNA, scrambled control siRNA (gray bars), or siRNA against GSK3a (blue bars) (n = 5). ii: GSK-3a-specific blot. iii: Flow
cytometry profiles of GSK-3a, GSK-3b, and PD-1.
(E) i: Cytolytic assays using other GSK-3 inhibitors. ii: Flow cytometry profiles of PD-1 in the presence or absence of the specific inhibitor (gray line, isotype control;
green line, scrambled siRNA; red line, inhibitor).
Error bars based on triplicate values in individual experiments; data shown representative of five independent experiments.
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effective in blocking the induction of Pdcd1 transcription by anti-
CD3 over 72 hr (Figure 3A). GSK-3 siRNA also inhibited Pdcd1
transcription in OT-I T cells in response to EL-4-OVA cells (Fig-
ure 3B). In addition, SB415286 blocked Pdcd1 transcription in
OT-I responses to EL4-OVA (Figure 3C). A titration of structurally
distinct inhibitors such as CT99021, AR-AO14418, and TZD8
also inhibited Pdcd1 transcription, whereas the phosphatase in-
hibitor NSC 87877 had no effect (data not shown).
Conversely, we found that SB415286 increased the transcrip-
tion of Tbx21 (encodes T-box transcription factor T-bet) concur-
rent with Pdcd1 inhibition. This was observed in response to
anti-CD3 ligation without affecting Tcf7-mediated transcription
(Figure 3A). Similarly, GSK-3 siRNA in OT-I T cells increased
Tbx21 transcription in response to EL4-OVA (Figure 3B) as did in-
cubation with SB415286 for 5 and 6 days (Figure 3C). Chromatin
immunoprecipitation (ChIP) with two different anti-T-bet anti-
bodies followed by PCR confirmed that GSK-3 inhibition
increased T-bet binding to Pdcd1 in anti-CD3-activated primary
or Jurkat T cells (Figure 3D). Further, anti-CD3 activation of cells
expressing the Ifng CNS-12 promoter construct driven by T-bet
(Kanhere et al., 2012) and incubated with SB415286 showed that
increased transcription (Figure 3E). These data confirm that
GSK-3 inactivation acted to increase Tbx21 transcription and
its binding to the PD-1 promoter.
We next examined whether GSK-3 mediated its effect on
Pdcd1 transcription via T-bet (Figure 3F and 3G). T-bet siRNA
expression decreased the presence of T-bet transcripts while
increasing PD-1 transcription consistent with its negative regula-
tion of PD-1 (Kao et al., 2011). At the same time, SB415286 failed
to reduce PD-1 expression in cells expressing T-bet siRNA, as
assessed by flow cytometry. Similar findings were observed
using OT-I CTL killing as a read-out (Figure 3G). T-bet siRNA
impaired CTL killing over different E:T ratios as well as reducing
GZMB and Lamp1 expression (Figure 3G). This inhibition was
completely reversed by PD-1 blockade showing that the T-bet
inhibition of CTL OT-I responses was due primarily to increased
PD-1 expression. By contrast, SB415286 failed to reverse the in-
hibition of killing by T-bet siRNA. This result indicated that the
modulatory effects of GSK-3 on PD-1 expression operated in a
pathway that required the expression of T-bet.
As an additional control, we also re-expressed PD-1 in
SB415286-exposedOT-I T cells and assessedwhether this could
reverse the enhancement of CTL killing (Figure 3H). EL-4-OVA-
activated SB415286-treated cells were transfected on day 5 of
A
B
C
D
Figure 2. GSK-3 Potentiates OT-I Cytolytic Killing of EL4-OVA Target Cells via the Downregulation of PD-1
(A) Percent target killing of EL4-OVA targets by OT-I CD8+ CTLs expressing scrambled or GSK-3 siRNA in the presence or absence of blocking anti-PD-1 or
PDL1-Fc.
(B) Percent killing of EL4-OVA targets by OT-I CD8+CTLs incubated in the presence or absence of SB415286with or without blocking anti-PD-1 or PDL1-Fc. OVA
alone: light gray bars; anti-PD-1: dark blue bars; PD-L1-Fc: light blue bars (n = 4).
(C) Relative Pdcd1 expression in the presence and absence of PD-1 siRNA and/or SB415286.
(D) Percent target killing from conditions in (C).
Error bars based on triplicate values in individual experiments; data shown representative ofR4 independent experiments.
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culture with PD-1 followed by an assessment of cytolysis 48 hr
later. The SR alpha promoter plasmid with PD-1 (pPD1) induced
PD-1expression similar to levels on activatedT cells. This expres-
sion reversed the enhanced killing induced by SB415286, con-
firming that PD-1 downregulation was responsible for the poten-
tiating effects of GSK-3 inactivation on CTL function.
Another possible connection to GSK-3 was the transcription
factor NFATc1 because GSK-3 inhibition increases nuclear
NFATc1 in CD4+ T cells (Beals et al., 1997; Neal and Clipstone,
2001). Pdcd1 expression is regulated by NFAT2 (Oestreich
et al., 2008) and NFAT binding sites exist inTbx21 (Martinez
et al., 2015). NFATc1 siRNA downregulated nfat transcripts
(Figure S3A). However, unlike GSK-3 inhibition, NFATc1 siRNA
inhibited all events including T-bet (Figure S3B) and PD-1
(Figure S3C) transcription and CTL killing (Figure S3D).
Cyclosporin A (CsA) treatment also inhibited Tbx21, Pdcd1,
and CTL killing and SB415286 was unable to rescue the inhibi-
tory effect (Figures S4A–S4D).
In Vivo GSK-3 Inhibition Decreases PD-1 Expression and
Enhances CTL Function of CD8+ OT-I T Cells
To assess the in vivo effect of GSK-3 inactivation on PD-1
expression, we initially examined the in vivo generation of OT-I
responses to OVA peptide in the presence of SB415286. OVA
peptide was injected intravenously (i.v.) into OT-I transgenic
mice with and without SB415286 followed by the harvest of
A
F G
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Figure 3. GSK-3 KD or Drug Inactivation Inhibits PD-1 and Increases Tbx21 Transcription and Binding to the Pdcd1
(A–C) Tbx21 andPdcd1 transcription in response to anti-CD3 activation with or without SB415286 (A) (n = 4), siRNAGSK-3a/bKD inOT-I cells in response to OVA
(B) (n = 3), and in OT-I T cells responding to OVA peptide with and without SB415286 (C) (n = 3).
(D) ChIP using anti-T-bet antibodies 2-H10 and 4B10 followed by PCR analysis of Pdcd1 promoter. Mouse T cells (left); Jurkat T cells (right).
(E) Tbx21-driven Ifng CNS-12 promoter activity in response to CD3 with or without SB415286.
(F) Effect of T-bet siRNA on Pdcd1 and Tbx21 transcription (top). Flow cytometry of PD-1 expression on T cells expressing scambled siRNA or T-bet siRNA in the
presence or absence of SB415286 (bottom).
(G) CTL killing efficiency of T-bet siRNA-expressing CTLs in the presence of anti-PD-L1 blockade and/or SB415286 and on expression of GZMB and Lamp1
expression in T-bet siRNA-expressing OT-I cells (n = 3).
(H) Killing efficiency of OT-I CTLs exposed to SB415286 followed by pPD-1 expression and flow cytometric profile of restored PD-1 expression (n = 3).
Error bars based on triplicate values in individual experiments; data shown representative ofR3 independent experiments.
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spleens and lymph nodes (LNs) at day 7 (Figure 4A) or a repeat
injection of the drug at day 7 followed by a harvest on day 14 (Fig-
ure 4B). T cells from extracted spleens/LNs were then assessed
for the ex vivo killing of EL4-OVA targets. From this, the in vivo
injection with SB415286 resulted in a 2- to 5-fold increased
killing efficiency of ex vivo extracted CTLs over a range of E:T
ratios. qPCR of extracted T cells also confirmed that in vivo
exposure to SB415286 inhibited Pdcd1 transcription. These
data provided initial evidence that the in vivo inhibition of
GSK-3 with a small molecular inhibitor suppressed PD-1 expres-
sion for enhanced CTL function.
GSK-3 Regulates Clearance of Herpes MHV-68 Virus
Infection via PD-1 Downregulation
We were next interested in whether small molecule inhibitors of
GSK-3 could treat viral infections via downregulation of PD-1.
To test this, we infected BALB/c mice intra-nasally with the
luciferase+ Murid herpesvirus 68 (MHV-68), an isolate of Murid
herpesvirus 4 (MuHV-4) (Stevenson et al., 1999), in the presence
or absence of SB415286. Viral luciferase expression effectively
tracks the spread of infection as monitored by luciferin injection
and CCD camera scanning (Milho et al., 2009). The presence of
virus was followed over time from the nose to lung alveoli where
lytic replication occurs. In theMHV-68model, day 7 corresponds
to the latent period and day 14 to chronic infection (Stevenson
et al., 1999). We found that SB415286 markedly reduced the
luciferase signal in the nose and lungs in mice as assessed on
day 7 (Figures 5A and S5B). Quantitative comparisons of
maximum radiance confirmed an increase in the presence of
luciferase+ MHV-68 in lungs from day 3 to 7, which drug treat-
ment reduced from 106-7 to 104-5 ps-1. The viral load (plaque
forming units [pfu]) was also significantly reduced from 6 3 104
to 1 3 104 at day 7 and from 2 3 104 to 4 3 103 at days 7 and
14 (Figure 5B). Quantitative real-time PCR of T cells extracted
BA Figure 4. GSK-3 Inactivation In Vivo Sup-
presses PD-1 and Increases T-bet Expres-
sion Concurrent with Enhanced OT-I CTL
Function
SB415286 administered in vivo on days 0 or 7 and
cells purified ex vivo on days 7 or 14. Ex vivo pu-
rified T cells were then assessed for cytolytic ac-
tivity (percent target killing) and qPCR for Pdcd1
expression on days 7 (A) and 14 (B). Mean and SD
of six mice per group.
from spleens of SB415286-treated mice
showed a reduction in pdcd1 transcrip-
tion concurrent with an increase in T-bet
expression (Figure 5C). Moreover, splenic
T cells from mice treated with SB415286
and tested ex vivo for the killing of targets
pulsed with MHV-68-derived peptide
M291–99 showed an increase in killing ca-
pacity (Figure 5D).
To assess whether the GSK-3 modula-
tion of PD-1 expression was responsible
for this effect, we next conducted the
same experiment using a combination of
anti-PD-1 blockade with SB415286 (Figure 5E). Anti-PD-1
blockade reduced viral spread as seen by the reduction in max
radiance (i.e., from 4 3 107 to 8 3 105 ps-1) when assessed on
days 3, 5, and 7. SB415286 reduced the maximum radiance to
the same degree, and importantly, when used in combination,
anti-PD-1 blockade had no further effect than SB415286, and
vice versa. Measurement of viral titers at days 7 and 14 showed
that anti-PD-1 blockade and SB415286 reduced viral titers to
the same extent (Figure 5F). Further, the injection of anti-PD-1
did not increase the response further in mice injected with
SB415286 and vice versa. These observations showed that the
effect of GSK-3 inhibition in vivo in response to MHV-68 was
mediated via PD-1 downregulation.
Lastly, the increase in viral clearance due to GSK-3 inhibition
was accompanied by an increase in Lamp1 (i.e., from 120
to 210 GeoMFI, p < 0.001), GZMB (i.e., from 11 to 14GeoMFI,
p < 0.001), and IFN-g (i.e., from 29 to 43 GeoMFI, p < 0.05)
expression (Figure 5G). By contrast, the presence of SB415286
did not alter the frequency of cells expressing CD44 and
CD62L (Figure 5H), in accord with studies on Pdcd1/ T cells
(Keir et al., 2007). Cells expressing CD4 also did not change.
By contrast, M291–99 tetramer staining showed increased
numbers of M2 peptide-specific CD8+ T cells (Figure 5I). Overall,
our findings show that the in vivo inactivation of GSK-3 can
significantly reduce the progression of MHV-68 infection in
mice due to reduced PD-1 expression.
GSK-3 Augments Clearance of Chronic LCMV-Cl13
Infection
Exhausted virus-specific CD8+ T cells during chronic infection
are characterized by prolonged expression of PD-1 in response
to the lymphocytic choriomeningitis virus variant LCMV-Cl13
(Ahmed et al., 1984; Barber et al., 2006; Day et al., 2006). This
contrasted with the LCMV Armstrong strain (LCMV-Arm) that
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induces a more robust response and resolves within 8–10 days.
To assess the role of the GSK-3-T-bet-PD-1 pathway in LCMV-
Cl13 infection,micewere infected i.v.with the LCMV-Cl13 variant
followed by an injection with SB415286 at day 25 when exhaus-
tion had been established in the chronic phase of the infection
(Figure S5C). Mice were then monitored on days 23, 25, 30,
and 37. DbGP33-41 peptide staining of CD8
+ T cells from mice
infected with LCMV-Cl13 demonstrated high expression of
PD-1, unlike T cells from LCMV-Arm-infected mice. Further,
DbGP33-41
+CD8+ T cells from mice treated with SB415286
showed a significant reduction in global PD-1 expression relative
to untreated mice, when assayed on days 25 and 30 (Figure 6A).
PD-1 expression was inversely related with an increase in T-bet
expression (r2=0.7) (Figure 6B). Consistentwith PD-1downregu-
lation, SB415286-treatedmice had a significant reduction in viral
load in blood at days 30 and 37 (Figure 6C). When expressed as
percent infectivity compared to day 23 (Figure 6D), mice showed
a range of responses with more than a log reduction between
some untreated and treated mice (i.e., 102 from control mice to
5 3 102), as reported in response to anti-PD-1 (Brooks et al.,
2008; Ha et al., 2008; West et al., 2013). This was accompanied
by a slight increase in the number of GP33-41
+CD8+ T cells
A
D
G H I
E F
B C
Figure 5. In Vivo GSK-3 Inhibition Increased Acute MHV-68 Viral Clearance via PD-1 Downregulation
BALB/c mice were intra-nasally infected with MHV-68 with/without an i.p. injection of SB415286.
(A) Histogram showing maximal radiance values on days 3, 5, and 7 (n = 20).
(B) Histogram showing viral titers at days 7 and 14 (n = 5).
(C) qPCR values of Pdcd1 and Tbx21. Gray bars, non-treated; blue bars, SB415286 treated. Each column represents a different mouse.
(D) CTL killing of EL4-M2 cells (percent target killing). T cells isolated from spleen were assessed for ex vivo killing of EL4-M2 cells (n = 3).
(E and F) BALB/c mice were infected with MHV-68 and treated with anti-PD1 with and without SB415286 undergoing the same regime as in (A) (n = 3). Radiance
values on days 3, 5, and 7 (E); viral titers on days 7 and 14 (F).
(G) Flow cytometry profile of Lamp1, GZMB, and IFN-g expression (n = 3).
(H) Flow cytometry profiles of CD44, CD62L, and CD4 expression. Gray line, isotype control; green line, T cells stimulated with OVA peptide alone; red line, T cells
stimulated with OVA peptide in the presence of SB415286.
(I) Absolute numbers of M2 peptide-specific CD8+ T cells.
Mean and SD of at least five mice per group. Also see Figures S5A and S5B.
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(Figure 6E). By contrast, SB415286 treatment had no obvious
effect on cell number (Figure 6F) or PD-1 expression (Fig-
ure 6G) of CD4+ T cells (CD11a+CD49d+CD4+) from mice
infected with LCMV-Cl13. LCMV-specific CD4+ T cells express
CD11ahiCD49d+ (McDermott and Varga, 2011).
Further, GP33-41
+CD8+ T cells showed a significant increase in
the percentage of cells expressing IFN-g and tumor necrosis fac-
tor-alpha (TNF-a) at days 30 and 37 induced by SB415286 (Fig-
ure 6H). As a positive control, the Armstrong strain of the virus
also showed increased numbers of cells expressing IFN-g
and TNF-a. These data showed that the inhibition of the GSK-3
pathway can also modulate PD-1 expression during LCMV-
Cl13 chronic infection that is associated with T cell exhaustion.
DISCUSSION
Despite the importance of PD-1 in modulating T cell responses,
the upstream pathway responsible for PD-1 downregulation
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Figure 6. GSK-3 Inhibition In Vivo Can Enhance Viral Clearance in Chronic Infection by LCMV-Cl13
Mice were infected i.v. with LCMV-Cl13 and treated with/without SB415286.
(A) Flow cytometry depicting PD-1 expression on DbGP33-41 CD8
+ T cells in LCMV-Cl13-infected mice treated with and without SB415286. Right plot represents
MFI values for PD-1 expression DbGP33-41 CD8
+ T cells at 23–40 days after infection (n = 2). Blue box, DMSO-treated LCMV-Cl13-infected mice; red box,
SB415286-treated LCMV-Cl13-infected mice; white box, LCMV-Arm control.
(B) Inverse relationship between PD-1 and T-bet in mice treated with SB415286 (boxes as in A; each box represents a different mouse).
(C) Viral load in serum of LCMV-Cl13-infected mice treated with or without SB415286. pfu/ml viral titers in serum (3105) days 23, 30, and 37.
(D) Percent infectivity at days 30 and 37 compared to day 23.
(E) Number of DbGP33-41 CD8 T cells taken from the spleens of mice, treated with or without SB415286 over 30–40 days.
(F and G) Number of CD4+ T cells (CD11a+CD49d+CD4+) (F) and total number of CD4+ cells (G) from mice infected with LCMV-Cl13 and treated with or without
SB415286.
(H) Flow cytometry profiles of IFN-g- and TNF-a-expressing T cells frommice infectedwith LCMV-Arm control (day 37) or LCMV-Cl13 (day 25, 30, 37). Histograms
(linear scale and log scale) showing the numbers of DbGP33-41CD8
+ T cells expressing IFN-g and TNF-a after GP33-41 peptide stimulation of PBMCs ex vivo from
untreated and SB415286-treated mice. Blue boxes, DMSO-treated mice; red boxes, SB415286 treated; white boxes, LCMV-Arm control. Each box represents a
different mouse. Data represent two combined independent experiments of nR 4 mice per group.
Statistics for (B) were done by 2-way ANOVA, (C) and (E) by non-parametric Mann-Whitney at each time point. *p < 0.05, **p < 0.01, ***p < 0.001.
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expression has yet to be defined. Here, we have identifiedGSK-3
as a key upstream kinase that regulated PD-1 expression and
enhanced CD8+ CTL function for the in vivo clearance of MHV-
68 and LCMV-Cl13 viral infections. GSK-3 inactivation operated
in a pathway that increased Tbx21 transcription that in turn in-
hibited Pdcd1 transcription and expression for enhanced CD8+
CTL killing efficiency. We also demonstrated the use of small
molecular inhibitors of GSK-3 to reduce PD-1 expression for
enhanced in vivo immunity.
Previous studies have shown that GSK-3b inhibits the prolifer-
ation and development of CD4+ T cells (Beurel et al., 2011; Oh-
teki et al., 2000; Schroeder et al., 2013; Wood et al., 2006). Our
findings provided an additional mechanism to account for inhibi-
tion where inactivation of GSK-3a/b downregulates PD-1,
thereby removing the inhibitory effect of the co-receptor on pro-
liferation. Its downregulation by siRNA, or chemical inhibition,
potently inhibited PD-1 transcription in CD8+ T cells resulting in
an enhancement of OT-I killing of targets by 5- to 10-fold. In a
screen of receptors, only the expression of PD-1 on CD8+
T cells was inhibited. PD-1 blockade, either in vitro or in vivo,
did not increase the enhanced killing efficiency of CTLs induced
by GSK-3 inactivation, or vice versa. If GSK-3 operated primarily
via a different pathway, additional effects of GSK-3 inhibition
beyond PD-1 blockade would have been expected. Further,
the ectopic PD-1 expression completely reversed the enhance-
ment of killing efficiency induced by GSK-3 inhibition. Although
GSK-3 can regulate the expression of numerous other genes,
our findings underscored the dominance of GSK-3’s effect on
PD-1 on CD8+ CTL function. In accord, PD-1 has previously
been shown to inhibit the generation of cytolytic T cells (Okazaki
et al., 2002). A range of structurally distinct competitive and
non-competitive inhibitors inhibited PD-1 transcription, whereas
the phosphatase inhibitor NSC 87877 had no effect (data not
shown).
Our findings also demonstrated the in vivo application of
small molecule inhibitors of GSK-3 for the downregulation of
PD-1 in immune therapy. Injection of SB415286 and other in-
hibitors enhanced OT-I CTL in vivo responses, as well as the
clearance of acute or chronic infection by MHV-68 and
LCMV-Cl13. GSK-3 inhibition reduced PD-1 expression and
LCMV-Cl13 viral titer by a half log when administered during
the exhaustion phase of infection. As with anti-PD-1 blockade,
a range of effect was seen among individual mice with as much
as a log reduction in infection between control and SB415286-
treated mice. These effects were similar to those reported with
VV/GP33 (Ha et al., 2008) and in anti-PD1-treated mice (i.e., a
half log difference) (Brooks et al., 2008) as well as in Tbx21/
mice (Kao et al., 2011). GSK-3 inhibition also restored the func-
tionality of exhausted GP33-41
+CD8+ T cells as evidenced by the
increased expression of TNF-a and IFN-g. The connection to
IFN-g is intriguing given reports of an impairment of IFN-g in
patients carrying certain PD-1 polymorphisms (Kroner et al.,
2005). Our findings suggest that GSK-3 inhibitors could be
used to substitute or complement anti-PD-1 or PD-L1 therapy
presently in use in infection and cancer (Barber et al., 2006;
Day et al., 2006; Freeman et al., 2006; Grakoui et al., 2006;
Ha et al., 2008; Wolchok et al., 2013) or in combination
with CTLA-4 blockade (Topalian et al., 2015; Wolchok et al.,
2013).
Mechanistically, we found that GSK-3 inhibition operated by
increasing the transcription of T-bet, a central regulator of Th1
cell differentiation (Glimcher, 2007). Surprisingly, this connection
between GSK-3 and T-bet had not previously been reported and
could have a range of functional implications to T cell differenti-
ation and function. In CD8+ T cells, GSK-3 inactivation increased
Tbx21 transcription for enhanced T-bet expression that in turn
inhibited Pdcd1 transcription. We showed by ChIP analysis
that GSK-3 inactivation increased T-bet binding to the Pdcd1
promoter and confirmed with siRNAs that T-bet negatively regu-
lates Pdcd1 transcription (Kao et al., 2011; Wherry et al., 2007).
Importantly, we found that GSK-3 downregulation of PD-1 was
dependent upon T-bet expression as shown by the inability of
SB415286 to downregulate PD-1 on T-bet siRNA-expressing
cells. In our model, GSK-3 acts as a suppressor of a suppressor
of a suppressor, namely PD-1. Upon activation, GSK-3 is in-
hibited by TCR/CD28-induced phosphorylation leading to
increased T-bet expression and the development of effector
function. In the case of CD28, GSK-3 inactivation involves its
binding and activation of phosphatidyl-inositol 3 kinase (PI3K)
and protein kinase B (AKT) (Prasad et al., 1994; Rudd and
Schneider, 2003). However, the inactivation process is ineffi-
cient, allowing the induction of some PD-1 expression via the
general activation of T cells. The application of drug or interfering
RNAs allowed for a more complete inactivation of GSK-3 and
reduced PD-1 expression. Remarkably, we also noted that
PD-1 blockade reversed T-bet siRNA inhibition of OT-I CD8+
CTL responses, indicating that altered PD-1 expression can ac-
count for much of the T-bet regulation of CTL function.
It also appeared that T-bet did not affect the transcription of all
its potential promoters in CD8+ T cells. For example, although
T-bet binds to the Tim3 promoter (Anderson et al., 2010), we
saw no consistent effect of GSK-3 inhibition on Tim3 expression.
This could be related to chromosomal accessibility or other fac-
tors affected by GSK-3 signaling. However, despite the domi-
nance of PD-1 in CD8+ T cells, GSK-3 could potentially still
directly affect other genes that might alter CTL function in other
conditions such as cancer. For example, T-bet binding sites exist
in the GZMB and IFN-g promoters (Martinez et al., 2015). In other
words, an increase in GZMB and IFN-g is due to PD-1 downre-
gulation with an additional contribution direct GSK-3 upregula-
tion of GZMB and IFN-g gene expression. We did not observe
an effect on CD44 or CD62L expression, agreeing with reports
of normal CD44/CD62L expression on pdcd1/ T cells (Keir
et al., 2007).
The connection of GSK-3-T-bet-PD-1 axis to other signaling
events is also possible. The transcription factor FoxO1 sustains
expression of PD-1 during chronic LCMV-Cl13 infection
involving increased PKB/AKT activity (Staron et al., 2014). Notch
positively regulates PD-1 transcription (Mathieu et al., 2013),
whereas activator protein 1 (AP1) and Blimp1 (B-lymphocyte
maturation protein 1) suppresses it (Lu et al., 2014; Xiao et al.,
2012). By contrast, although cytokine receptors increase PD-1
expression via STATs (Signal transducers and activators of tran-
scription) (Kinter et al., 2008), these do not obviously intersect
with antigen-receptor signaling in T cells.
In CD4+ T cells, GSK-3 inhibition increases the residency of
nuclear NFATc1 (Beals et al., 1997; Neal and Clipstone, 2001),
whereas Pdcd1 expression is regulated by NFAT2 (Oestreich
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et al., 2008). Whether this pathway is connected to GSK-3 regu-
lation of PD-1 in effector CD8+ T cells is unclear because we
failed to observe an effect of GSK-3 inactivation on PD-1 expres-
sion on CD4+ T cells during LCMV-Cl13 infection. Whether this
lack of an effect will be seen in other in vivo contexts needs to
be clarified. The situation is also complicated by the fact that
NFATc1 regulates many events (Macia´n et al., 2001; Masuda
et al., 1998). In our hands, NFATc1 inactivation inhibited T-bet,
PD-1 transcription, and CTL killing; this contrasts with GSK-3
inactivation in CD8+ T cells, where PD-1 transcription was in-
hibited but T-bet transcription and CTL function were increased.
An NFAT1 mutant unable to bind to AP-1 promotes CD8+ T cell
exhaustion (Martinez et al., 2015). NFAT2 has been reported to
be primarily nuclear in tolerant CD8+ T cells (Srinivasan and Frau-
wirth, 2007), although others have reported that NFAT2 is not nu-
clear in exhausted T cells (Agnellini et al., 2007). We previously
found a connection between NFATc1 and adaptors ADAP and
SKAP1 in PD-1 expression indirectly due to suboptimal conjuga-
tion and activation of T cells (Li et al., 2015). These different
findings underscore a complexity of NFAT in interfacing with
different activation events in T cells. Overall, the full therapeutic
potential of GSK-3 inhibitors in the downregulation of PD-1 in
the treatment of infection and cancer remains to be clarified.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 and BALB/c (Harlan UK) mice were housed at the Central Biological
Services (Cambridge University). Mice were infected when 6–8 weeks old un-
der the HomeOffice Project License 80/2189. Antibodies andGSK-3 inhibitors
are described in the Supplemental Experimental Procedures.
In Vitro Assays
Primary mouse T cells (OT-I, C57/b6) were isolated from spleens and cultured
in vitro in supplemented RPMI 1640 (Raab et al., 2010; Veale et al., 1999). T cell
enrichment was performed with T cell purification columns (R&D Systems).
OVA-specific CD8+ cytolytic T cells were generated by incubating OT-I spleno-
cytes with SIINFEKL peptide of OVA (OVA257-264) at 10 ng/mL for 5–7 days,
usually in experiments using SB415286 such as in Figure 1B. Alternatively,
EL-4 cells were incubated with 10 nM OVA257-264 peptide (Bachem) for 1 hr
at 37C and treated with mytomycin C (Sigma-Aldrich) (final concentration of
10 mg/mL) prior to mixing with primary T cells by co-culturing at a ratio of 1:5
of EL4 and T cells in order to generate cytotoxic T cells.
CTLs were generated in the presence or absence of inhibitors and/or anti-
PD-1 or anti-PDL-1 blockade for 5–7 days prior to washing and analysis by
FACs or PCR or in cytoxicity assays. In some cases, naive OT-I T cells were
first incubated with OVA peptide with or without GSK-3 inhibitors and/or
anti-PD-1 or PD-L1-Fc (1–3 mg/mL). 25 mM stock solutions were prepared
in DMSO and diluted to a concentration of 1–10 mM in vitro. NSC 87877 was
used at 50 mM (Tocris Bioscience Boston Biochem) (Song et al., 2009) and
cyclosporin A (CsA) (Sigma) at 0.5 mg/mL.
In certain cases, naive cells were subjected to nuclear transfection in the
presence of various siRNA oligos (i.e., GSK-3). 3.0–5.0 mg of siRNAs were
added to 1 3 106 T cells and suspended in 100 mL of nucleofector solution
for T cells (Amaxa Biosystems). Cells were electroporated with a Nucleofector
(Amaxa Biosystems), as previously described (Smith et al., 2013; Valk et al.,
2006). In certain instances, pre-activated T cells were transfected with mouse
PD-1 (Takebe et al., 1988).
For in vitro cytotoxic assays, transfected T cells were plated in 96-well plates
at the start of culture with activating EL4 cells pulsed with OVA peptide except
in the case of the MHV-68 in which EL4s were pulsed with the M2 peptide
(M291–99, GFNKLRSTL) (SIGMA-Genosys) (Husain et al., 1999). Cytotoxicity
was assayed with a Cytotox 96 nonradioactive kit (Promega) according to
the instructions provided.
Luciferase reporter assays were performed with Dual-luciferase Reporter
Assay System (Promega).
Quantitative Real-Time PCR and Chromatin Immunoprecipitation
Single-strand cDNA was synthesized with an RT-PCR kit (QIAGEN) and
phases of PCR amplification were monitored to ensure a measurement of
real-time transcription (Wacker and Godard, 2005). ChIP (Pierce Agarose
ChIP kit) was conducted according to the manufacturer’s protocols (Thermo
Scientific #26156).
Viruses and In Vivo Luciferase Imaging
Luciferase tagged-MHV-68 viral stock isolation, infection, and imaging were
conducted as described (de Lima et al., 2004) and in Supplemental Experi-
mental Procedures. Mice received treatment on days 0, 3, 5, 7, and 10 of either
PBS, SB415286 (10 mg/kg), or anti-PD1/PD-L1 (100 mg per dose/mouse) intra-
peritoneally (i.p.). For luciferase imaging, mice were injected i.p. with luciferin
(2 mg per mouse), anesthetized with isoflurane, and scanned with an IVIS
Lumina (Caliper Life Sciences) as previously described (Milho et al., 2009).
For LCMV, LCMV-Arm and LCMV-Cl13 strains were prepared as described
(Harker et al., 2011, 2013). Mice were infected i.v. with 2 3 106 pfu of LCMV-
Arm or LCMV-Cl13. Mice received doses of SB415286 or PBS every 48 hr
from day 23 until day 37. LCMV titers in the serum were determined by vero
cell plaqueassays asdescribedpreviously. Viruseswere alsogrown, identified,
and quantified as described (Ahmed et al., 1984; Borrow et al., 1995).
In Vivo Priming OT-I Tg Cells
OVA peptide (1 mg) was injected i.v. into OT-I Tg mice with and without
SB415286 (10 mg) on days 0 and 7. T cells were purified from spleens har-
vested on days 7 and 14.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2016.01.018.
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